Hematopoietic cell transplant (HCT) patients with low socioeconomic status (SES) have reduced survival and increased transplant-related mortality (TRM) ([@pkz073-B1],[@pkz073-B2]). These differences are partially attributable to differential health behaviors and medical care access ([@pkz073-B3]), but SES-related disparities in cancer outcomes remain even after accounting for such differences ([@pkz073-B4],[@pkz073-B5]). Psychobiological processes involving stress physiology and immune activation may also contribute to SES-related disparities in treatment outcomes ([@pkz073-B6],[@pkz073-B7]). Social environmental conditions influence a variety of physiological processes ([@pkz073-B8]) including gene regulation in both healthy and diseased tissues ([@pkz073-B12]). One genomic response of particular significance for HCT involves sympathetic nervous system-mediated activation of a leukocyte transcriptional program known as the conserved transcriptional response to adversity (CTRA). The CTRA biological pattern can be assessed in transcriptome profiling data in several ways, including 1) an a priori-specified composite score involving 53 indicator genes for inflammation and Type I interferon response, 2) transcript origin analyses (TOA) assessing increased activity of monocytes in general and classic monocytes in particular, and 3) activity of pro-inflammatory and antiviral transcription factors ([@pkz073-B15]). This transcriptional shift is observed during extended periods of stress, threat, or uncertainty ([@pkz073-B15],[@pkz073-B16],[@pkz073-B19]) and is mediated by both per-cell changes in gene expression and by myelopoietic up-regulation of the pro-inflammatory CD16^−^ classic monocyte subpopulation ([@pkz073-B19]).

CTRA profiles are elevated in circulating leukocytes from healthy low-SES individuals ([@pkz073-B12],[@pkz073-B19]). In a small pilot study (N = 78), we recently observed that low SES is also associated with elevated CTRA profiles in pre-transplant peripheral blood mononuclear cell (PBMC) samples from HCT recipients with acute myelogenous leukemia (AML) ([@pkz073-B14]). Univariate analyses demonstrated increased relapse and decreased leukemia-free survival (LFS) in individuals showing high CTRA patterning. SES-related differences in CTRA gene expression may represent one biological pathway underlying socioeconomic disparities in HCT outcomes. Independent of SES, CTRA profiles may constitute a useful molecular biomarker for predicting treatment failure risks. This study includes a larger sample size, multivariable statistical analyses, and additional measures of CTRA biology to further explore the relationships among SES, leukocyte gene regulation, and clinical outcomes in unrelated donor HCTs for AML. These analyses also allowed mapping of the molecular and cellular pathways previously implicated in CTRA expression as well as population dynamics of CD16^−^ classic monocytes.

Methods
=======

Data Sources
------------

The Center for International Blood and Marrow Transplant Research (CIBMTR) is a working group of more than 450 HCT centers that report all transplants consecutively with compliance audits and longitudinal patient follow-up. CIBMTR studies comply with federal regulations protecting human research participants.

Participants
------------

This study included patients older than 18 years with AML in first or second complete remission who underwent a T-replete, unrelated myeloablative fully matched (8 of 8) adult donor peripheral blood or bone marrow transplant from 1995 to 2005 with available residential US zip code information and blood samples at transplant time (N = 264). Mean household income was estimated from patient residential zip code 2006--2010 Census Bureau data ([@pkz073-B22]). Three patients had zip codes without a correlative match and were excluded. Race was reported by transplant centers and categorized according to the US Office of Management and Budget classification. The institutional review board of the National Marrow Donor Program approved all study procedures. All recipients consented to participate in the CIBMTR Research Repository and database.

Analysis of CTRA Biology
------------------------

Total RNA was extracted from cryopreserved PBMCs (RNeasy; Qiagen), tested for integrity (Bioanalyzer; Agilent), and converted to fluorescent cRNA for hybridization to Illumina Human HT-12 v4 BeadArrays ([@pkz073-B23]). All 264 samples yielded valid results as assessed by endpoint quality assurance metrics (median hybridization intensity \>100 fluorescence units). We analyzed the CTRA physiological pattern using three different convergent analyses. The first examined a prespecified 52-gene composite score comprised of 19 pro-inflammatory genes (*IL1A*, *IL1B*, *IL6*, *IL8*, *TNF*, *PTGS1*, *PTGS2*, *FOS*, *FOSB*, *FOSL1*, *FOSL2*, *JUN*, *JUNB*, *JUND*, *NFKB1*, *NFKB2*, *REL*, *RELA*, and *RELB*) weighted positively to indicate their direct association with the CTRA pattern and 30 type I interferon genes (*GBP1*, *IFI27*, *IFI27L1-2*, *IFI30*, *IFI35*, *IFI44*, *IFI44L*, *IFI6*, *IFIH1*, *IFIT1-3*, *IFIT5*, *IFIT1L*, *IFITM1-3*, *IFITM4P*, *IFITM5*, *IFNB1*, *IRF2*, *IRF7-8*, *MX1-2*, *OAS1-3*, and *OASL*) and three antibody synthesis genes (*IGJ*, *IGLL1*, and *IGLL3*) weighted negatively to indicate their inverse association ([@pkz073-B16],[@pkz073-B24]). These indicators represent the entire 53-gene CTRA indicator set used in previous research with the exception of *IFI1*6, which was unavailable due to random variations in microarray synthesis ([@pkz073-B25]).

The second analytic approach used the transcriptome data to derive estimates of transcription control pathway activity for prespecified pro-inflammatory and antiviral transcription factors. These analyses employed the TELiS promoter-based bioinformatic analysis to assess activity of NF-κB, activator protein 1, and interferon response factors ([@pkz073-B26]). Ancillary analyses also examined activity of neuroendocrine signaling pathways upstream of the CTRA (cAMP response element-binding protein and the glucocorticoid receptor).

The third analytic approach assessed the specific leukocyte subsets mediating the observed differences in gene expression using TOA as previously described ([@pkz073-B14],[@pkz073-B23]). Briefly, TOA forms cell-specific diagnostic scores for each gene using reference transcriptome profiles of isolated cell samples, and the specific gene sets derived from this study's analyses are tested for overrepresentation of diagnostic scores for each cell type to identify the predominant cellular origin of SES effects (eg, due to differential abundance of that cell and/or selective transcriptional activation of that cell type). Analyses used reference data on isolated monocytes, B cells, CD4^+^ and CD8^+^ T cells, natural killer cells, and plasmacytoid dendritic cells (Gene Expression Omnibus series GSE1133) as well as classic (CD16^−^) and nonclassic (CD16^+^) monocyte subsets (GSE25913). The original TOA method uses group-level identification of differentially expressed genes. To provide an individual-specific measure of cell subset-related gene expression suitable for clinical outcome prediction, we applied TOA to the set of genes that were relatively up-regulated in each patient's sample (≥2 SD above the sample average for that gene) or relatively down-regulated (≥2 SD below the sample average) after screening out genes that showed minimal expression above background (average \< 7.04 log~2~ RNA abundance) or minimal variation in expression across samples (SD \< 0.074 log~2~ RNA abundance, corresponding to \<1.10-fold variation across the 4-SD range spanning 95% of individuals under a normal distribution). Interested investigators can submit a CIBMTR proposal for data access approval.

Clinical Outcomes
-----------------

Primary clinical outcomes were relapse (with TRM as the competing risk) and LFS (survival in complete remission after HCT, with events being either disease relapse or treatment-related death). Additional outcomes included neutrophil engraftment at day +28 (absolute neutrophil count \>0.5 × 10^9^/L sustained for three consecutive days), acute and chronic graft-vs-host disease (GVHD; death without GVHD is the competing risk, with patients censored at subsequent transplant or last follow-up), TRM (death from any cause by day +28 days regardless of relapse status; death beyond day +28 considered transplant related if disease was in remission), and overall survival (death from any cause). Time-to-event outcomes all start at time of HCT. The median follow-up time is about 10 years ([Table 1](#pkz073-T1){ref-type="table"}).

###### 

Patient, disease, and treatment characteristics[\*](#tblfn1){ref-type="table-fn"}

  Characteristic                                      No. (%)
  --------------------------------------------------- ---------------
  Patients, n                                         261
  Recipient age, median (range), y                    44 (18--68)
  Recipient age at transplant, y                      
   18--19                                             3 (1)
   20--29                                             55 (21)
   30--39                                             40 (15)
   40--49                                             105 (40)
   50--59                                             53 (20)
   60--69                                             5 (2)
  Recipient sex                                       
   Male                                               115 (44)
   Female                                             146 (56)
  Recipient race                                      
   White                                              248 (95)
   African-American                                   4 (2)
   Asian                                              1 (\<1)
   Other                                              3 (1)
   Unknown                                            5 (2)
  Recipient BMI                                       
   Underweight (\<18.5 kg/m^2^)                       6 (2)
   Normal (18.5--25 kg/m^2^)                          85 (33)
   Overweight (25--30 kg/m^2^)                        83 (32)
   Obese (≥30 kg/m^2^)                                85 (33)
   Missing                                            2 (\<1)
  Karnofsky score before transplant                   
   \<90                                               50 (19)
   ≥90                                                185 (71)
   Missing                                            26 (10)
  Type of AML                                         
   De-novo AML                                        205 (79)
   Therapy-related AML                                15 (6)
   Secondary AML with previous diagnosis of MDS/MPS   39 (15)
   Missing                                            2 (\<1)
  Prior autologous HCT                                
   No                                                 251 (96)
   Yes                                                10 (4)
  Donor age, median(range), y                         34 (20--59)
  Graft type                                          
   Bone marrow                                        128 (49)
   Peripheral blood                                   133 (51)
  Donor age at transplant, y                          
   18--32                                             122 (47)
   33--49                                             128 (49)
   ≥50                                                11 (4)
  Donor-recipient sex match                           
   M-M                                                84 (32)
   M-F                                                82 (31)
   F-M                                                31 (12)
   F-F                                                64 (25)
  Donor race                                          
   White                                              225 (86)
   African-American                                   4 (2)
   Asian                                              3 (1)
   Native American                                    5 (2)
   More than one race                                 8 (3)
   Other                                              7 (3)
   Unknown                                            9 (3)
  Donor BMI                                           
   Underweight (\<18.5 kg/m^2^)                       3 (1)
   Normal (18.5--25 kg/m^2^)                          45 (17)
   Overweight (25--30 kg/m^2^)                        66 (25)
   Obese (≥30 kg/m^2^)                                45 (17)
   Missing                                            102 (39)
  Donor-recipient CMV match                           
   −/−                                                79 (30)
   −/+                                                96 (37)
   +/−                                                34 (13)
   +/+                                                51 (20)
   Missing                                            1 (\<1)
  ABO incompatibility                                 
   Matched                                            118 (45)
   Minor mismatch                                     53 (20)
   Major mismatch                                     70 (27)
   Bi-directional                                     19 (7)
   Missing                                            1 (\<1)
  Cytogenetics scoring                                
   Favorable                                          34 (13)
   Intermediate                                       108 (41)
   Poor                                               66 (25)
   Not tested                                         20 (8)
   Missing                                            33 (13)
  Conditioning regimen (MA only)                      
   TBI+Cy                                             113 (43)
   TBI+other                                          37 (14)
   Bu+Cy                                              91 (35)
   Mel+Thio                                           2 (\<1)
   Bu+Flud                                            14 (5)
   Mel+Flud                                           3 (1)
   Bu+Clad                                            1 (\<1)
  Median income, US\$                                 
   \<34 700                                           21 (8)
   34 700--43 600                                     48 (18)
   43 601--56 300                                     77 (30)
   \>56 300                                           115 (44)
  GVHD prophylaxis                                    
   Tac-based                                          140 (54)
   CSA-based                                          116 (44)
   Missing/other                                      5 (2)
  Year of transplant                                  
   1995--2000                                         68 (26)
   2001--2003                                         80 (31)
   2004--2005                                         113 (43)
   CD34 cell dose, 10^6^/kg                           6 (\<1--34)
  Time from diagnosis to transplant                   8 (\<1--133)
  Median follow-up of survivors (range), mo           120 (27--218)

\*AML = acute myelogenous leukemia; BMI = body mass index; Bu = busulfan; Clad = cladribine; CMV = cytomegalovirus; CSA = cyclosporine; Cy = cyclophosphamide; Flud = fludarabine; GVHD = graft-vs-host disease; MA = myeloablative; MDS = myelodysplastic syndrome; Mel = melphalan; MPS = myeloproliferative syndrome; Tac = tacrolimus; TBI = total body irradiation; Thio = thiotepa.

Statistical Analyses
--------------------

### SES and CTRA Biology

SES was represented using annual income value cut-points previously reported ([@pkz073-B14]): lowest quartile (\<\$34 700), middle two quartiles (\$34 700--\$56 300), and highest quartile (\>\$56 300). Analyses controlled for age, race, sex, body mass index category, AML type, prior autologous transplant, Karnofsky performance score, and interval from diagnosis to transplant. When a given outcome was tested for association with multiple hypothesized predictors, analyses compared for multiple comparisons following standard statistical protocols in biomedical research ([@pkz073-B27]). Where indicated, ancillary analyses also controlled for specific gene mRNA transcripts marking the prevalence of T lymphocytes and their subsets (CD3D, CD3E, CD4, CD8A), B lymphocytes (CD19), natural killer cells (CD16/FCGR3A, CD56/NCAM1), and monocytes (CD14) ([@pkz073-B20]) to ensure results were not confounded by variations in leukocyte subset prevalence ([@pkz073-B28]). Throughout all bioinformatics analyses, standard errors for summary statistics were derived from 200 bootstrap resamples of residual vectors to account for potential correlation among residuals across genes; *P* values were derived from *t* statistics based on these bootstrap-estimated standard errors ([@pkz073-B29]). To evaluate SES association with CTRA, analyses tested 1) an a priori-defined contrast score representing up-regulated expression of 19 pro-inflammatory genes and down-regulated expression of 30 genes involved in type I interferon responses and three in antibody synthesis, as described above; 2) a transcription factor-based analysis in which the promoter DNA sequences of all genes showing greater than 1.2-fold differential expression in low- vs high-SES transcriptome profiles were scanned for transcription factor-binding motifs (TFBMs) for pro-inflammatory and Type I interferon-related transcription factors using TRANSFAC position-specific weight matrices V\$CREL_01, V\$AP1_Q6, and V\$ISRE_01 (as well as V\$CREB_02 and V\$GR_Q6 to assess ancillary hypotheses about related neuroendocrine signaling pathways) ([@pkz073-B26]), with differential activity inferred from the ratio of TFBM prevalence in up- vs down-regulated gene sets and log~2~-transformed ratios averaged over nine parametric variations of TRANSFAC MatInspector scan stringency and promoter length ([@pkz073-B26],[@pkz073-B30]); and 3) a cell-based analysis in which all genes showing more than 1.2-fold differential expression in low- vs high-SES transcriptome profiles were mapped to cell diagnostic scores using TOA as previously described ([@pkz073-B14],[@pkz073-B23],[@pkz073-B30]) (reference data derived from GSE1133 and GSE25913 as described above). Point estimates of TFBM effect size served as inputs into bioinformatics analyses because previous research finds that it yields more reliable gene lists and bioinformatic results than does *P/q-*value screening ([@pkz073-B24],[@pkz073-B30]).

### CTRA Biology and Clinical Outcomes

Patients were grouped based on quartiles of CTRA indicator gene composite scores (and subcomponents in follow-up analyses), and these associations were also tested on a continuous scale. Continuous TOA scores (cellular origin scores for genes up- and down-regulated in association with SES) were evaluated in association with HCT outcomes. Due to the impact of CTRA inflammatory patterns on monocyte biology, total monocyte TOA scores were also assessed as predictors of clinical outcomes. (No attempt was made to relate transcription factor activity to clinical outcomes because that analysis utilizes group-based estimates of differential gene expression and thus does not yield a patient-specific score that could be used to predict clinical outcomes.) The association of patient-, disease-, and transplant-related characteristics with CTRA contrast scores (and their subcomponents) in quartiles was tested by standard χ^2^ test (or Fisher exact test for counts ≤5) for categorical variables or Kruskal-Wallis test for continuous variables. We stabilized variance across genes by z-score transformation to eliminate heteroscedasticity before computing the CTRA or TOA composite score for each individual. The association of SES or CTRA composite score quartiles with overall survival and LFS was tested using the log-rank test. Probabilities of overall survival and LFS were estimated using the Kaplan-Meier estimator, and the probabilities of TRM, relapse, neutrophil engraftment, and a/cGVHD were assessed by the cumulative-incidence function method. Cox proportional-hazards regression models were used to control for patient baseline characteristics in quantifying relationships between CTRA or TOA scores and clinical outcomes. All the patient-, disease-, and demographic-related variables considered in the SES analysis were examined. The proportional hazards assumption was assessed for each candidate variable and outcome using a time-dependent covariate approach. Prognostic variables were selected for each outcome separately using stepwise model selection (*P* \< .05 for entry and retention). All *P* values are two-sided. Data analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

Results
=======

Patient Characteristics
-----------------------

Each variable ([Table 1](#pkz073-T1){ref-type="table"}) was tested for association with SES, with most not statistically significant. However, a minority showed association and were therefore controlled for in subsequent analyses of CTRA biology, including more male recipients in the highest SES quartile (N = 39 in Q4 vs N = 27, 25, 24 in Q1--Q3, respectively; *P* = .03). There was also a statistically significant difference in donor-recipient sex match (more female-male and fewer male-female matches in the highest SES quartile; N = 15 in Q4 vs N = 5, 7, 4 in Q1--Q3, respectively; *P* = .02) and GVHD prophylaxis (tacrolimus-based regimens were more prevalent in the highest SES quartile; N = 39 in Q4 vs N = 29, 21, 21 in Q1--Q3, respectively; *P* = .03).

Molecular Correlates of SES
---------------------------

Low SES was not associated with the 52-gene CTRA composite score (or its subcomponents) utilized in our previous study ([@pkz073-B14]) despite the fact that gene-specific SES association measures derived from this sample correlated *r* = 0.50 with those observed previously ([Figure 1A](#pkz073-F1){ref-type="fig"}) ([@pkz073-B14]). However, low SES was associated with two other bioinformatic indicators of CTRA-related transcription factor activation: increased NF-κB and activator protein 1 ([Figure 1, B and C](#pkz073-F1){ref-type="fig"}). As in the previous study, genes up-regulated in low SES samples derived predominantly from monocytes (*P* = .03; [Figure 1D](#pkz073-F1){ref-type="fig"}) and from classic (CD16^−^) monocytes more specifically (*P* \< .001; [Figure 1E](#pkz073-F1){ref-type="fig"}). Reciprocally, genes up-regulated in high-SES recipients derived predominantly from nonclassic (CD16^+^) monocytes (*P* = .04; [Figure 1E](#pkz073-F1){ref-type="fig"}).

![**A--E**) Expression of the conserved transcriptional response to adversity gene set, transcription control pathways, and cellular origin. **A**) Gene-specific socioeconomic status (SES) associations derived from current sample vs prior pilot sample ([@pkz073-B14]). Genes showing ≥20% difference in expression between hematopoietic cell transplant recipients of low- vs high-SES (**B**) and low- vs middle-SES (**C**) groups were tested for differential activity of specific transcription factors as indicated by Transcription Element Listening System analysis of transcription factor-binding motifs in proximal promoter sequences of up- vs down-regulated genes ([@pkz073-B26]). Genes up-regulated in low-SES samples generally derive from monocytes (**D**), and more specifically from classic (CD16^−^) monocytes (**E**). Genes down-regulated in low SES derive predominantly from nonclassic (CD16^+^) monocytes (**E**). \**P* \< .05, \*\**P* \< .01. In D and E, \*\* values would remain statistically significant after correction for multiple testing, whereas \* would not. Displayed data (**B--E**) are single model-derived parameter estimates with associated standard errors.](pkz073f1){#pkz073-F1}

CTRA Associations with Transplant Outcomes
------------------------------------------

The association of SES with clinical outcomes did not reach statistical significance likely due to limited power to detect the previously observed effect size ([@pkz073-B1]). The CTRA composite score was not statistically significant when its association was tested with clinical outcomes. However, when the 19-gene pro-inflammatory subcomponent and 30-gene antiviral/antibody-related subcomponent were examined separately, the pro-inflammatory subcomponent was associated with relapse ([Figure 2A;](#pkz073-F2){ref-type="fig"}[Table 2, *P*](#pkz073-T2){ref-type="table"} = .002) and LFS ([Figure 3](#pkz073-F3){ref-type="fig"}; [Table 2, *P*](#pkz073-T2){ref-type="table"} = .03) when examined categorically. Univariate modeling revealed similar patterns. As shown in [Figures 2--3](#pkz073-F2){ref-type="fig"} and [Table 2](#pkz073-T2){ref-type="table"}, outcome risks were relatively elevated in the lowest and highest quartiles of inflammatory gene expression compared with those in the middle two quartiles (ie, a U-shaped or bipolar risk profile). Outcome risks did not differ between the lowest and highest quartiles. As such, transplant recipients in the highest or lowest quartiles of the CTRA pro-inflammatory gene component had a more than 2-fold elevated hazard of relapse (hazard ratio \[HR\] = 2.47, 95% confidence interval \[CI\] = 1.44 to 4.24), *P* = .001; HR = 2.52, 95% CI = 1.46 to 4.34, *P* = .001) and greater than 20% reduction in LFS (HR = 1.57, 95% CI = 1.08 to 2.28, *P* = .012; HR = 1.49, 95% CI = 1.04 to 2.15, *P* = .03) compared with the middle quartiles. Quadratic trend analysis of the continuous pro-inflammatory CTRA score also yielded a statistically significant association with relapse ([Table 2, *P*](#pkz073-T2){ref-type="table"} = .01) and LFS ([Table 2, *P*](#pkz073-T2){ref-type="table"} = .02).

![Cumulative incidence of relapse by molecular indicator. **A**) Pro-inflammatory conserved transcriptional response to adversity subcomponent is associated with relapse. **B**) Down-regulation of total monocyte-derived transcripts is associated with relapse (again, high scores indicate more down-regulation). CTRA = conserved transcriptional response to adversity.](pkz073f2){#pkz073-F2}

![Probability of leukemia-free survival by pro-inflammatory conserved transcriptional response (CTRA) to adversity expression. LFS = leukemia-free survival.](pkz073f3){#pkz073-F3}

###### 

Clinical outcome models for pro-inflammatory CTRA molecular predictors of clinical outcomes

                                                                                              No. of patients   HR (95% CI)           *P*
  ------------------------------------------------------------------------------------------- ----------------- --------------------- ------
  Relapse[∗](#tblfn2){ref-type="table-fn"} (categorical; overall *P* = .002)                                                          
   Pro-inflammatory CTRA score                                                                                                        
    ≤−5.47                                                                                    63                1.00 (reference)      
     (\>−5.47, 0.14)                                                                          65                0.38 (0.20 to 0.75)   .005
     (\>0.14, 5.83)                                                                           64                0.41 (0.21 to 0.80)   .009
    \>5.83                                                                                    65                0.98 (0.57 to 1.68)   .95
  Relapse∗ (continuous)                                                                                                               
   Parameter                                                                                                                          
    Pro-inflammatory CTRA linear                                                                                0.95 (0.78 to 1.15)   .60
    Pro-inflammatory CTRA quadratic                                                                             1.10 (1.02 to 1.18)   .01
  Leukemia-free survival[†](#tblfn3){ref-type="table-fn"} (categorical; overall *P* = .025)                                           
   Pro-inflammatory CTRA score                                                                                                        
    ≤−5.47                                                                                    63                1.00 (reference)      
    (\>−5.47, 0.14)                                                                           64                0.56 (0.36 to 0.87)   .01
    (\>0.14, 5.83)                                                                            62                0.79 (0.52 to 1.20)   .26
    \>5.83                                                                                    61                1.06 (0.70 to 1.61)   .80
  Leukemia-free survival[†](#tblfn3){ref-type="table-fn"} (continuous)                                                                
   Parameter                                                                                                                          
    Pro-inflammatory CTRA linear                                                                                1.00 (0.87 to 1.16)   .97
    Pro-inflammatory CTRA quadratic                                                                             1.08 (1.01 to 1.15)   .02

No adjusted covariates entered into the model. CI = confidence interval; CTRA = conserved transcriptional response to adversity; HR = hazard ratio.

Disease, GVHD prophylaxis, and graft types were adjusted in the model.

Total monocyte activation (monocyte TOA scores) was also significantly associated with clinical outcome risk. Relapse risk was related to categorical TOA scores representing down-regulation of total monocyte-derived transcripts ([Figure 2B;](#pkz073-F2){ref-type="fig"}[Table 3](#pkz073-T3){ref-type="table"}; *P* = .01), with high TOA scores indicating more monocyte down-regulation. Continuous monocyte TOA scores showed similar risk patterning with up-regulated scores associated with decreased relapse ([Table 3](#pkz073-T3){ref-type="table"}; *P* = .001) and down-regulated scores associated with increased relapse ([Table 3](#pkz073-T3){ref-type="table"}; *P* = .001). When evaluated continuously, monocyte TOA scores were additionally associated with LFS as well, with up-regulated scores associated with decreased LFS ([Table 3](#pkz073-T3){ref-type="table"}; *P* = .01) and down-regulated scores associated with increased LFS ([Table 3](#pkz073-T3){ref-type="table"}; *P* = .01). Overall survival, TRM, neutrophil engraftment, and a/cGVHD did not reveal a statistically significant association with monocyte biology in general.

###### 

Clinical outcome models for total monocyte population molecular predictors of clinical outcomes

                                                                                No. of patients   HR (95% CI)           *P*
  ----------------------------------------------------------------------------- ----------------- --------------------- ------
  Relapse[\*](#tblfn4){ref-type="table-fn"} (categorical; overall *P* = .012)                                           
   Down-regulated gene total monocyte TOA score                                                                         
    ≤−0.5029                                                                    65                1.00 (reference)      
     (\>−0.5029, −0.1039)                                                       64                1.08 (0.52 to 2.30)   .84
     (\>−0.1039, 0.3700)                                                        64                2.39 (1.24 to 4.61)   .01
    \>0.3700                                                                    63                2.15 (1.09 to 4.22)   .03
  Relapse∗ (continuous)                                                                                                 
   Up-regulated gene total monocyte TOA score (linear)                                            0.52 (0.35 to 0.78)   .001
   Down-regulated gene total monocyte TOA score (linear)                                          1.71 (1.23 to 2.36)   .001
  Leukemia-free survival[†](#tblfn5){ref-type="table-fn"} (continuous)                                                  
   Up-regulated gene total monocyte TOA score (linear)                                            0.71 (0.54 to 0.92)   .01
   Down-regulated gene total monocyte TOA score (linear)                                          1.32 (1.06 to 1.63)   .01

\*No adjusted covariates entered into the model. CI = confidence interval; HR = hazard ratio; TOA = transcript origin analyses.

†Disease, GVHD prophylaxis, and graft types were adjusted in the model.

Discussion
==========

These data link low SES to two distinct aspects of leukocyte transcriptome alteration in the blood of AML patients before HCT: increased activity of pro-inflammatory transcription factors (NF-κB and AP-1) and increased activity of monocytes, in general, and classic monocytes in particular. Moreover, some aspects of this CTRA molecular profile appear to portend increased risk of adverse clinical outcomes during HCT for low-SES patients, because the complementary profiles of reduced inflammatory gene expression and monocyte activation more broadly are both associated with decreased post-transplant relapse and enhanced LFS. Some aspects of this profile are consistent with our previous pilot data ([@pkz073-B14]) linking low SES to enhanced expression of the stress-related CTRA biological pattern, which is mediated by pro-inflammatory transcription factor activation and increases in classic monocytes at the expense of nonclassic monocytes. However, other aspects of the present results are not consistent with those earlier findings ([@pkz073-B14]), including the absence of a statistically significant SES relationship with a prespecified 52-gene CTRA indicator score. Regardless of the specific mechanisms involved, these data identify inflammation and myeloid lineage-related transcriptome profiles that may serve as predictive biomarkers to prospectively identify patients at risk of HCT treatment failure. Alterations in myeloid lineage-related immunoregulation could also represent an intervention target to reduce the risk of adverse HCT outcomes generally, and particularly for low-SES individuals.

Although the present results are broadly consistent with our previous findings in relating low-SES and HCT outcomes to myeloid lineage gene regulation ([@pkz073-B14]), the results from this more robust analysis differ in several respects. They provide greater evidence of pro-inflammatory transcription factor activation, possibly due to increased statistical power in this larger sample. They also yield less pronounced association of the previous 53-gene CTRA indicator gene profile with clinical outcomes, possibly due to a subset of rogue transcripts in this data set (see off-diagonal gene values in [Figure 1A;](#pkz073-F1){ref-type="fig"} this finding likely relates to effects of more heterogenous disease status in this sample, although specific mechanisms remain a topic for future research). Another difference is that these data identified a U-shaped bipolar risk for the CTRA inflammation index ([Figure 4](#pkz073-F4){ref-type="fig"}). This curvilinear relationship may be a reflection of SES-related gene regulation at one pole and general post-transplant dyspoiesis related to adverse HCT outcomes at the other ([@pkz073-B36]). The U-shaped relationship may suggest that, in addition to SES- and CTRA-related biological influences, inflammatory molecular patterns may also detect occult residual AML influences on hematopoiesis and/or leukocyte population dynamics. The present findings do not identify a statistically significant effect of classic vs nonclassic monocyte expression on HCT outcomes despite their association with SES; however, this may be due to limited statistical power as was observed in the relationship between SES and clinical outcomes in this sample. Importantly, the genomic indicators statistically significantly related to both SES and clinical outcomes---relapse and LFS---are consistent in both this analysis and our previous study ([@pkz073-B14]).

![The conserved transcriptional response to adversity (CTRA) inflammation index demonstrates a U-shaped bipolar risk profile for relapse. Social environmental- or socioeconomic-related factors (CTRA consistent) may be responsible for one pole of influence, and hematologic or hematopoietic factors reflective of overall dyspoiesis may be associated with the other risk pole. SES = socioeconomic status.](pkz073f4){#pkz073-F4}

This study's findings are limited in several respects. They focus on a one-time, cross-sectional, pretransplant assessment of PBMC gene expression during a specified period; future studies are needed to determine whether the recipient SES-related gene expression profiles vary throughout the transplant process or differentially affect outcomes in a time-dependent manner and in a more contemporary cohort. The observed associations may also be attributable in part to other related chronic stress factors associated with SES, including but not limited to depressed mood ([@pkz073-B37]) and low social support ([@pkz073-B38]); genomic alterations as presented here may be indicative of a more comprehensive overall stress biomarker. Future work should use larger samples to conduct formal statistical mediation analyses evaluating a direct mechanistic model between SES and clinical outcomes. Other potential factors influencing differences in HCT immune function and biology, such as adolescent and young adult status, should also be considered. Although zip code has been robustly associated with both HCT ([@pkz073-B1],[@pkz073-B14]) and general health outcomes ([@pkz073-B39]), future research should consider more sensitive and individual-specific SES measures, including address, self-reported income, insurance status, and employment ([@pkz073-B40],[@pkz073-B41]). Because this study tests several distinct substantive hypotheses, the multiple findings reported here will be important to replicate.

In summary, this study identifies SES-related gene expression among unrelated donor HCT recipients with AML to include increased activity of pro-inflammatory transcription control pathways, increased activation of classic monocytes, and a complementary decrease in activity of nonclassical monocytes, all of which are consistent with the CTRA physiologic pattern relating stress and sympathetic nervous system activation to altered regulation of gene expression in myeloid lineage immune cells. Multivariable modeling indicates a statistically significant effect for this general molecular pattern as predictive of worse clinical outcomes, including relapse and LFS. These findings provide a molecular framework within which to understand social environmental influences on immunobiology and clinical outcomes in the setting of cancer and HCT.
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